Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Carisma Therapeutics Inc CARM

Healthcare Biotechnology
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the... see more

Recent & Breaking News (NDAQ:CARM)

Sesen Bio Announces Commercial Manufacturing and Global Supply Partnership with Qilu Pharmaceutical

Business Wire December 7, 2020

Sesen Bio Announces Partnership with Hikma Pharmaceuticals for the Commercialization of Vicineum(TM) in the Middle East and North Africa

Business Wire December 1, 2020

Sesen Bio Reports Third Quarter 2020 Financial Results and Positive Progress Towards Completing the BLA Submission for VicineumTM in December 2020

Business Wire November 9, 2020

Sesen Bio to Host Conference Call to Review Third Quarter Financial Results and Provide an Update on Positive Progress Towards Demonstration of Analytical Comparability

Business Wire November 2, 2020

Sesen Bio Announces Successful Pre-Submission Meeting with the European Medicines Agency for Vicineum(TM)

Business Wire October 26, 2020

Sesen Bio Announces an Exclusive Agreement With Cardinal Health for Third-Party Logistics and Specialty Pharmaceutical Distribution Services for Vicineum(TM)

Business Wire October 19, 2020

Sesen Bio to Provide Business Update at the H. C. Wainwright 22nd Annual Global Investment Conference

Business Wire September 8, 2020

Sesen Bio Reports Second Quarter 2020 Financial Results and Business Update

Business Wire August 10, 2020

Sesen Bio to Present Regulatory and Business Development Update at the Canaccord Genuity 40th Annual Growth Conference

Business Wire August 5, 2020

Sesen Bio announces an exclusive license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum(TM) in Greater China

Business Wire July 31, 2020

Sesen Bio to Host Conference Call to Provide OUS Business Update

Business Wire July 30, 2020

Sesen Bio to Present at the Jefferies Virtual Healthcare Conference

Business Wire May 26, 2020

Sesen Bio Reports First Quarter 2020 Financial Results and Meaningful Progress Towards Demonstrating Analytical Comparability

Business Wire May 11, 2020

Sesen Bio Reports Positive Interactions with EMA on Regulatory Pathway for Vicinium®

Business Wire May 7, 2020

Sesen Bio to Host Conference Call to Review First Quarter Financial Results and to Provide Operational Update Highlighting Positive Progress Towards Demonstrating Analytical Comparability

Business Wire May 4, 2020

Sesen Bio Reports Fourth Quarter and Full-Year 2019 Financial Results

Business Wire March 16, 2020

Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Business Update Highlighting Regulatory Progress and Commercial Opportunity for Vicinium®

Business Wire February 25, 2020

Sesen Bio Announces Changes to the Board of Directors as the Company Advances Toward Commercialization of Vicinium®

Business Wire February 24, 2020

Sesen Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 31, 2020

Sesen Bio Completes Successful CMC Type B pre-BLA Meeting with FDA

Business Wire December 4, 2019